SMYD3 and breast cancer: Fifty-eight out of 65 (89.2%) cases had SMYD3 expression in their BC tumors, while only 5 out of 65 (7.7%) of the matched normal tissues exhibited weak positive cytoplasmic staining (P<0.001, χ2-test) (Figure 1A).